Island Pharmaceuticals appoints highly experienced US biodefence executive Mark Herzog as Senior Global Health Security Advisor

MELBOURNE Australia, 19 May 2026: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to provide the following update on US biodefence ecosystem engagement initiatives, implemented prior to the commencement of its planned dose escalation study next quarter to support the development of Galidesivir for the treatment of Marburg Virus Disease (MVD) under the US Food & Drug Administration’s (FDA) Animal rule. Most recently, Island has expanded its engagement across the US biodefence landscape with the appointment of Mr Mark Herzog as Senior Global Health Security Advisor. In parallel, the Company is also advancing a number of initiatives as part of its membership of the Medical Countermeasures Coalition (MC2), an international alliance focused on advancing vaccines, therapeutics and diagnostics targeting emerging infectious diseases and biological threats.

Appointment of Mark Herzog to expand US biodefence sector engagement:

Mr Herzog has over 25 years executive leadership experience across the biopharmaceutical, biodefence and clinical laboratory sectors, with particular expertise in global health security policy, medical countermeasure development, government affairs, defence acquisition and strategic stakeholder engagement. Most recently, he served 12 years in senior roles with a US pharmaceutical company focused on advanced drug delivery and medical countermeasure technologies, where he supported multiple US Department of Defence (DoD) and biodefence initiatives. Throughout his career, he has demonstrated a strong track record of developing and obtaining US$100m+ in US and international government contracts, leading FDA-approved product PR launches and building cross-sector coalitions across defence, public health and industry. Concurrently, he has positioned himself as a trusted advisor to senior government and industry stakeholders with deep expertise in DoD, Department of Human Health Services (HHS), the Biomedical Advanced Research and Development Authority (BARDA), North Atlantic Treaty Organisation (NATO) and allied procurement ecosystems.

Mr Herzog also serves on the executive committee of the Medical CBRN Defense Consortium (MCD), a leading US biodefence consortium supporting the development and procurement of medical countermeasures targeting chemical, biological, radiological and nuclear threats. As part of his engagement, Mr Herzog will assist Island in expanding its presence within the US biodefence and global health security ecosystem, with a focus on strategic government engagement, medical countermeasure policy, procurement pathways and pandemic preparedness initiatives. His appointment is expected to support Island’s ongoing advancement of Galidesivir under the FDA Animal Rule pathway for Marburg Virus Disease, while also strengthening the Company’s engagement with key US government agencies, biodefence stakeholders, strategic partners and procurement networks relevant to future medical countermeasure opportunities, including potential Strategic National Stockpile (SNS) inclusion.

For the full release, please visit: https://www.islandpharmaceuticals.com/site/pdf/73dbaddf-4cbc-499a-b015-3697452f3564/Island-Bolsters-US-Biodefence-Readiness-Ahead-of-Trials.pdf?Platform=ListPage

"The U.S. could face an existential threat as early as 2027."

"The U.S. could face an existential threat as early as 2027." That was one of the most striking takeaways from Assistant Secretary of Defense Bob Kadlec's remarks at the 2026 Medical CBRN Defense Consortium (MCDC) and Countering Weapons of Mass Destruction (CWMD) annual meeting this month.

 A few themes stood out:

The threat environment is changing rapidly.

Kadlec pointed to the bipartisan 2023 Strategic Posture Review which concludes that for the first time the U.S. now faces a two-peer nuclear challenge involving both China and Russia, while continuing to contend with emerging chemical and biological threats. Kadlec called the report "so stark, so profound and so startling" that he personally verified with six of its twelve commissioners whether they truly meant what they wrote. They did.

Medical countermeasure gaps remain significant.

Using the current hantavirus outbreak as an example, Kadlec highlighted the lack of broad-spectrum antiviral capabilities and emphasized the need for stronger coordination between DoD and HHS through the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE).

Operation Warp Speed remains a model worth replicating.

As one of its architects, Kadlec argued that the speed, flexibility, and public-private partnership approach used during COVID-19 should inform future development of diagnostics, therapeutics, and other medical countermeasures. He described his goal as a " warp speed for countermeasures" utilizing the Other Transaction Authorities (OTA) contracting pathway designed for speed, flexibility, and performance-based accountability that the traditional acquisition contracts cannot match.

Industry partnerships will be critical.

Kadlec closed by saying the Pentagon must work closely with its industry partners. "It's not as much your obligation to work with us. It's our obligation to work with you. You have the solutions. We've got to figure out how best to work with you effectively." He framed the current threat environment as categorically different from the war on terrorism or the post-Cold War era of rogue actors: "What we're facing is an existential threat that if we don't mount an effective, credible deterrent set of capabilities across the domain of nuclear, chemical, biological, and radiological, we will be out of business." Kadlec explained that, “When I say out of business, our life and our freedom and all the good things that we’ve enjoyed may never be the same.”

 Was this an overly pessimistic assessment—or a realistic appraisal of today's threat environment? For those who attended the meeting, I’d enjoy hearing what were your key takeaways?